1. Introduction
Magnetic nanoparticles represent a class of nanomaterials with inherent biocompatibility. Living organisms themselves synthesize certain magnetic nanoparticles through biomineralization processes, such as magnetotactic bacteria containing natural magnetic particles [
1,
2] and sensory organs in migratory birds that rely on the Earth’s magnetic field for navigation [
3]. In addition to naturally occurring magnetic nanoparticles, synthetic magnetic nanomaterials are also widely used in applications such as magnetic hyperthermia therapy for tumors and as components of composite materials for implantable devices. Experimentally validated magnetic nanoparticles demonstrate good cytocompatibility, extremely low hemotoxicity and genotoxicity, and a high median lethal dose (LD50), indicating that magnetic nanoparticles are promising materials with extensive biomedical application potential [
4,
5,
6,
7,
8,
9,
10,
11,
12,
13]. They can be injected into the bloodstream for magnetically guided drug delivery and perform tasks such as delivering targeted therapeutics for thrombolysis, after which they are degraded via metabolic pathways (e.g., in the liver) and excreted from the body, demonstrating their inherent biodegradability [
4,
14]. Regarding drug delivery carriers, numerous studies have shown that modified magnetic nanoparticles can be utilized for drug loading and delivery [
15,
16]. Concerning the synthesis of magnetic nanoparticles, particularly the widely used iron oxide (Fe
3O
4) nanoparticles, various methods exist, including coprecipitation, solvothermal synthesis, and thermal decomposition, et al. Among these, the solvothermal method is particularly suitable for large-scale synthesis of Fe
3O
4 nanoparticles due to its advantages in producing particles with controllable size, uniform distribution, and ease of surface modification [
17].
“Will injectable, disease-fighting nanobots ever be a reality?” is one of the 125 scientific questions for the 21st century proposed by
Science. Among them, the application of magnetic micro/nanorobots driven by alternating magnetic fields is inseparable from micro/nano structures primarily composed of magnetic nanoparticles. Based on magnetic materials of various morphologies and sizes, magnetic nanorobots can be constructed through methods such as layer-by-layer assembly [
18], surface modification [
19], and nanoparticle deposition [
20]. Examples include helical magnetic nanorobots fabricated by templated deposition on natural spiral microalgae [
20] and hematite nanorobots [
21] with dual-spherical structures. The primary functions of magnetic nanorobots are realized by tuning the magnetic nanoparticles and the nanorobot structure, with magnetic nanoparticles being a crucial component enabling external field manipulation and active targeted drug delivery [
22,
23]. Among the technical routes for modifying magnetic nanoparticles to equip them with various functions as nanorobots, coating magnetic nanoparticles with a mesoporous silica (mSiO
2) shell provides a substantial volume for drug loading. Simultaneously, the network of narrow and densely packed pores can retard drug release, enabling efficient drug encapsulation [
24]. The magnetic nanorobots composed of magnetic nanoparticles and mesoporous silica possess multiple advantages, including magnetically driven motion, precise manipulation, and targeted delivery, making them suitable for targeted drug delivery and therapy for diseases.
Inflammatory bowel disease (IBD) is a condition characterized by chronic, recurrent intestinal inflammation. Its global incidence continues to rise, posing a significant public health challenge [
25,
26]. Current therapeutic agents, such as glucocorticoids, primarily function through broad immunosuppression. However, these systemic treatments have notable limitations, including potential increased risks of infection and malignancy, potential long-term organ toxicity, and inadequate or lost response in some patients [
27,
28]. Consequently, there is a pressing clinical need to develop novel therapeutic strategies that combine good safety profiles with clear anti-inflammatory activity. In this context, natural active components derived from daily diets are considered highly promising candidate drug sources due to their widespread anti-inflammatory and antioxidant properties and relatively high safety profiles. Developing these dietary anti-inflammatory substances as adjunctive or alternative therapies for IBD aligns with the urgent clinical demand for safer and more accessible treatment options [
29,
30]. Capsaicin has garnered attention for its demonstrated anti-colitis activity in experimental models [
31]. Studies indicate that, within an appropriate dosage range, capsaicin can effectively ameliorate dextran sulfate sodium-induced colitis in mice. Its mechanisms involve downregulating the expression of pro-inflammatory cytokines such as IL-6 and IL-18, while enhancing the expression of intestinal tight junction proteins (e.g., ZO-1) and mucins, thereby remodeling the gut microbiota and repairing the intestinal mucosal barrier [
32,
33]. However, translating capsaicin into a clinically effective drug faces significant pharmacokinetic barriers: its high hydrophobicity leads to extremely low oral bioavailability; furthermore, its lack of specific distribution within the gastrointestinal tract results in most of an oral dose being absorbed or metabolized in the upper digestive tract, making it difficult to achieve and maintain effective therapeutic concentrations at colonic lesion sites. Particularly important is that capsaicin has a direct irritant effect on the gastrointestinal mucosa, especially in the anal region, leading IBD patients to often avoid consuming spicy products. This makes safe and effective administration in IBD patients extremely challenging.
Herein, to fundamentally address the critical limitations of conventional oral administration—specifically the severe mucosal irritation and low bioavailability of capsaicin—we developed a magnetic mesoporous silica nanorobot system (Cap-M@mSbots) designed for the active interventional prevention and targeted treatment of Inflammatory Bowel Disease (IBD), as schemed in
Figure 1. By encapsulating superparamagnetic Fe
3O
4 cores within a mesoporous silica shell, this composite structure not only shields the upper gastrointestinal tract from direct irritation but also serves as a high-capacity reservoir for the sustained release of anti-inflammatory agents. Crucially, distinguishing this work from passive nanocarriers, we introduce an active propulsion strategy driven by a rotating gradient magnetic field. Under this external actuation, the Cap-M@mSbots overcome Brownian motion to self-assemble into large-scale, reconfigurable linear swarms, exhibiting emergent collective locomotion with velocities reaching 180 μm/s. This swarm intelligence enables the nanorobots to navigate complex physiological environments, effectively surmounting millimeter-scale obstacles to achieve precise directional enrichment and prolonged retention at colonic lesion sites. Consequently, this active targeting capability significantly amplifies the therapeutic efficacy of capsaicin by restoring the intestinal mucosal barrier and down-regulating the NF-κB signaling pathway, thereby establishing a novel, safe, and efficient paradigm for the clinical management of colitis.
3. Results
The synthesis process of Cap-M@mSbots is illustrated in the schematic diagram in
Figure S1. In brief, magnetic nanoparticles are synthesized by the solvothermal method, a silicon source is introduced, and a silica shell layer is grown on the surface of the nanoparticles in situ. Finally, capsaicin is loaded into the interior. As shown in
Figure 2A, the results of STEM imaging and EDS mapping characterization for Cap-M@mSbots are presented. In comparison with the Magnetic NPs in
Figure S1, it can be observed that Cap-M@mSbots exhibit a core-shell structure. The EDS mapping shows distributions of iron and silicon elements consistent with a core-shell configuration, confirming that Cap-M@mSbots possess a core of magnetite (Fe
3O
4) nanoparticles surrounded by a silica shell.
Figure 2B and the corresponding
Figure S2 display a single Cap-M@mSbot imaged under conditions optimized for observation. Measurement of the shell thickness of Cap-M@mSbots indicates that the silica shell is approximately 20–30 nm thick. Furthermore, a line scan analysis was performed on the single Cap-M@mSbot shown in
Figure 2B, with the results presented in
Figure 2C. The line scan results suggest that the Cap-M@mSbot is fully encapsulated by the silica shell. The scanning data indicate an approximate atomic ratio of iron to silicon of about 3:1 in the sample, implying that the silica shell accounts for roughly 20% of the total mass of the Cap-M@mSbots. Additionally, the particle sizes of Magnetic NPs, M@mSiO
2 NPs, and Cap-M@mSbots were measured using Dynamic Light Scattering (DLS), as shown in
Figure 2D. The DLS results show average particle sizes of 222.6 nm for Magnetic NPs, 301.1 nm for M@mSiO
2 NPs, and 298.4 nm for Cap-M@mSbots. Since DLS measures the hydrodynamic diameter of nanoparticles in solution, the obtained values are larger than the dry-state particle sizes obtained from STEM measurements. Furthermore, the zeta potential of the gavage formulation containing Cap-M@mSbots was −18.2 mV. Moreover, due to the stronger hydrodynamic effects of the silica shell, the differences observed in the DLS results between particles with and without the silica shell are more pronounced compared to those from STEM measurements. To verify the magnetic properties of Cap-M@mSbots, hysteresis loops of Magnetic NPs, M@mSiO
2 NPs, and Cap-M@mSbots were measured using a vibrating sample magnetometer, with the results shown in
Figure 2E. The hysteresis loop exhibits no remanence or coercivity, confirming the superparamagnetic behavior of the samples. The saturation magnetization (Ms) values for the three samples are 11, 5, and 7 emu/g, respectively, which are lower than the generally reported range of 30–80 emu/g in the literature [
35,
36]. Apart from the influence of the mesoporous silica shell, this may also be attributed to the relatively coarse crystal growth resulting from the solvothermal synthesis method, leading to inconsistent internal crystallization directions within the nanoparticles, where partial magnetic fields cancel each other out upon magnetization.
Absorption spectra of Magnetic NPs, M@mSiO
2 NPs, and Cap-M@mSbots were measured using a UV-Vis-NIR spectrophotometer, as shown in
Figure 2F. The spectra in
Figure 2F are presented qualitatively, while the corresponding absorbance data are provided in
Figure S3. The results reveal a characteristic absorption peak of Capsaicin at a wavelength of 280 nm, which can be used to verify drug loading and release efficiency. The absorption spectrum of Magnetic NPs shows continuous absorption, with intensity gradually increasing as the wavelength decreases. The absorption spectrum of M@mSiO
2 NPs is similar to that of Magnetic NPs, with a slight enhancement in absorption in the 350–450 nm wavelength range, likely due to the difference in refractive index between the added silica shell and the Magnetic NPs. In the absorption spectrum of Cap-M@mSbots, the Capsaicin absorption peak is observable. Compared to the spectrum of pure Capsaicin, the peak is relatively attenuated, as the continuous absorption of Magnetic NPs masks a significant portion of the peak. The absorption spectroscopy confirms drug loading in Cap-M@mSbots. Next, the drug release performance of Cap-M@mSbots was evaluated. As shown in
Figure 2G, the drug release profiles of Cap-M@mSbots under different conditions are presented. The data indicate that after 48 h in water, Cap-M@mSbots release 4.3% of the loaded Capsaicin. In simulated gastric and intestinal fluids, the release proportions after 48 h are 13.8% and 19.8%, respectively. Considering the preventive effect of Capsaicin against colonic inflammation, Cap-M@mSbots are expected to exhibit sustained-release properties. The hydrophobic nature of Capsaicin and the narrow, elongated pores of the mesoporous silica shell contribute to achieving this sustained-release effect.
The motion of micro-nanorobots under magnetic field control is typically achieved using alternating magnetic fields with periodically changing directions, in which the rotational movement of the micro-nanorobots creates a rotating fluid field in the surrounding local space. By leveraging the asymmetry of the fluid field generated by their own asymmetric structures, the micro-nanorobots can achieve net displacement, or they can achieve autonomous motion through interactions with external surfaces such as substrates [
20]. For Cap-M@mSbots, due to their extremely small size, it may be challenging to achieve precessional motion similar to that of micron-scale robots under rotating magnetic fields. Therefore, by applying a rotating gradient magnetic field with a relatively high average magnetic field strength, under magnetic fields exceeding 20 mT, the individual Cap-M@mSbot is more likely to aggregate and couple their fluid fields, forming larger linear swarms under magnetic guidance. These linear swarms are more easily driven by magnetic fields and can disperse upon removal of the magnetic field after reaching the target location and simultaneously achieve the effect of phase separation, wherein the Cap-M@mSbot transitions from a uniformly distributed state to a non-uniformly distributed state within the dispersion system. Alternatively, by changing the magnetic field pattern, they can achieve long-term in situ residence. This driving mechanism is illustrated schematically in
Figure 3A, where one of the swarms is shown as an aggregate formed by a large number of Cap-M@mSbots.
Figure 3B and the corresponding
Video S1 demonstrate the process by which Cap-M@mSbots gradually form swarms under the influence of a rotating gradient magnetic field with an average magnetic field strength of 80 mT. Microscopic observations reveal that before the magnetic field driving device is activated, the Cap-M@mSbots are uniformly distributed within the field of view, resulting in an even grayscale image with no noticeable aggregation of Cap-M@mSbots. Upon applying the magnetic field, fluctuations in grayscale appear across the entire microscopic field of view. This occurs because the initially uniformly distributed Cap-M@mSbots simultaneously begin to move and rapidly undergo localized aggregation. Before reaching a scale observable by optical microscopy, these dynamics manifest as apparent changes in the overall grayscale of the field of view. As the aggregation process accelerates, linear aggregates of Cap-M@mSbots of varying lengths emerge in the field of view. These aggregates move forward rapidly in a tumbling motion as swarms, with some swarms achieving speeds exceeding 150 μm/s. Regarding the phenomenon of Cap-M@mSbots aggregating into linear swarms and performing collective motion under a rotating gradient magnetic field, control experiments were designed to investigate the effect of magnetic field strength on the length of the formed swarms. The statistical results are shown in
Figure 3C. Within 60 s of activating the magnetic field, the average length of swarms formed under an 80 mT magnetic field was 61.4 μm, while those under a 40 mT field averaged 51.2 μm in length, and those under a 20 mT field averaged 37.9 μm in length. These results indicate a positive correlation between magnetic field strength and the rate at which Cap-M@mSbots form swarms.
To observe the swarming locomotion of the Cap-M@mSbots more clearly, a portion of the field of view in
Video S1 was magnified, and motion trajectories were added using ImageJ software to visually demonstrate the movement state of the swarms. The results are shown in
Video S2. The motion trajectories were added using the Manuel tracking plugin, with the assistance of a mouse macro to determine the geometric center of the detected Cap-M@mSbot swarms. The results show that the movement speed of the counted swarms exceeds 100 μm per second, and the motion trajectory of the larger swarm exhibits a distinct zigzag pattern. It is suggested that this results from the asymmetric rotational effect of the rotating gradient magnetic field (RGMF). The gradient direction of the RGMF is not necessarily coplanar with the forward direction of the Cap-M@mSbot swarms, which may cause lateral traction during forward movement, resulting in periodic directional deviations. Furthermore, the relationship between the motion speed of swarms and the rotational frequency of the magnetic field under different magnetic field strengths was statistically analyzed, with the results shown in
Figure 3D. The data indicate that the motion speed of swarms generated by Cap-M@mSbots under a rotating gradient magnetic field initially increases and then decreases as the magnetic field rotational frequency rises, exhibiting a maximum value in motion speed. When the magnetic field strength is 20 mT, the maximum speed of the swarms occurs at a frequency of 7 Hz, reaching 115.9 μm/s. At a magnetic field strength of 40 mT, the maximum speed is observed at a frequency of 8 Hz, with a speed of 141.2 μm/s. When the magnetic field strength is 20 mT, the maximum speed appears at a frequency of 10 Hz, measuring 180.7 μm/s. Research on magnetically driven micro/nanorobots has shown that for such robots driven by rotating magnetic fields, there is an upper limit to their rotational angular velocity. When this limit is reached, increasing the rotational frequency of the magnetic field does not enhance the rotational speed of the micro/nanorobots, as their rotation can no longer keep up with that of the driving magnetic field due to limitations imposed by factors such as material properties and structural constraints. Consequently, the translational speed of the micro/nanorobots either reaches a maximum or begins to decline. When the motion speed of magnetically driven micro/nanorobots reaches its maximum as a function of magnetic field frequency, the corresponding frequency is defined as the cut-off frequency under those conditions. Beyond this frequency, further increases in rotational speed become ineffective. This corresponds to the frequency values associated with the maximum speeds observed under the various magnetic field strengths in the data above.
As the swarms generated by Cap-M@mSbots continue to move under the driving force of a rotating gradient magnetic field, localized fluid field coupling also occurs between approaching swarms. Unlike the fluid fields that drive swarm formation, the coupling between swarms in this case is insufficient to induce further fusion. Instead, it leads to coordinated motion in chain-like or ribbon-like formations when swarms come into close proximity, as shown in
Video S3. To more clearly demonstrate the ribbon-like formations formed by the swarms, segments of
Video S3 were captured and the motion trajectories were annotated using ImageJ software. The results are presented in
Video S4.
Video S4 provides a representative depiction of this collective swarming behavior, which is widely observed in
Video S3 as well as in the additional raw data referenced in this paper. To investigate the influence of inter-swarm coordination on motion speed, the effect of the number of swarms participating in coordinated motion on the ratio between the average translational speed of the system and the speed of a single swarm under the same conditions was analyzed. The results are presented in
Figure 3E. The data indicate that in over 80% of cases, the speeds of coordinated swarms fall within 80% to 120% of the speed of a single swarm under corresponding conditions. Moreover, the data exhibit randomness, suggesting no strong correlation between the number of swarms participating in coordinated motion and changes in swarm speed. The failure of further collective behavior to produce stronger motion effects may be attributed to the larger size of swarms, which results in greater fluid resistance, thereby limiting further fluid field coupling between different swarms. After verifying the motion performance of the swarms generated by Cap-M@mSbots under magnetic field actuation, it is essential to further discuss the feasibility of swarm motion in intestinal environments. To this end, the motion speeds of Cap-M@mSbots in PBS and simulated intestinal fluid were tested, with the results shown in
Figure 3F. The data indicate that at a magnetic field strength of 20 mT, the motion speed of the swarms in the simulated medium is 95.8% of their speed in water. At 40 mT, the speed in the simulated medium is 91.9% of that in water, while at 80 mT, it reaches 97.2% of the speed in water. These test results demonstrate that the motion of Cap-M@mSbots under alternating magnetic field actuation is largely unaffected by biological media. In addition to the influence of the medium, it is also necessary to consider the impact of intestinal geometric structures on the motion performance of swarms generated by Cap-M@mSbots. The intestinal lining contains numerous groove-like structures, and it is essential to verify whether the swarms can surmount such obstacles. As illustrated in
Figure 3G, the following experiment was designed to test the obstacle-crossing ability of the swarms: a block of agarose gel with a specific shape was adhered to a culture dish as an obstacle, with the agarose gel approximately 1 mm in height, far exceeding the possible dimensions of swarms formed by Cap-M@mSbots.
Figure 3H and the corresponding
Video S5 demonstrate the process of swarms generated by Cap-M@mSbots crossing the agarose gel barrier. A specific Cap-M@mSbot swarm arranged in a ribbon-shaped composite from
Video S5 was highlighted, with the results shown in
Video S6. During the climbing process, most swarms encounter obstacles of varying scales, yet the majority are able to consistently generate net displacement and ultimately overcome the obstacles. The swarms lined up to traverse the obstacle and maintained a speed exceeding 80 μm/s, confirming the feasibility of Cap-M@mSbots’ motion in complex environments.
Next, we systematically evaluated the preventive and therapeutic effects of the magnetically controlled mesoporous silica nano-delivery system loaded with capsaicin (Cap-M@mSbots) on DSS-induced colitis in mice. The experimental flowchart in
Figure 4A outlines the key time points: a three-week daily oral pretreatment with mesoporous silica-loaded capsaicin, during which the Cap-M@mSbots + MF group received local external magnetic field guidance after each administration, followed by a 10-day induction period with 2% DSS in drinking water and a 2-day recovery phase. In terms of clinical phenotypes, compared to the normal control group, the DSS model group exhibited significant progressive weight loss starting from the induction period (
Figure 4B), a sharp increase in the Disease Activity Index (DAI) score (
Figure 4C), and marked colon shortening (
Figure 4D). Preventive administration of Cap-M@mSbots partially alleviated these injuries, with its weight loss curve, DAI score, and colon length all significantly better than those of the DSS model group, although the improvement was limited. Furthermore, the Cap-M@mSbots + MF group with added magnetic guidance demonstrated far superior protective effects compared to the Cap-M@mSbots group, exhibiting higher protective efficacy. Specifically, the rate of weight loss in mice showed recovery relative to the Cap-M@mSbots group, accompanied by a reduction in DAI score and further restoration of colon length. These macroscopic data indicate that magnetic field-mediated active targeting significantly enhances the preventive efficacy of the nano-system against DSS-induced colitis.
At the level of inflammation and barrier function, ELISA assays revealed that serum TNF-α levels were significantly elevated in the DSS model group compared to the normal control group, while Cap-M@mSbots treatment effectively reduced these levels. Compared to the Cap-M@mSbots-only group, the Cap-M@mSbots + MF group exhibited the most pronounced inhibitory effect (
Figure 4E). Assessment of intestinal barrier integrity yielded consistent conclusions: mice in the DSS model group displayed markedly high intestinal permeability, as indicated by an increased FITC-Dextran ratio. Pretreatment with Cap-M@mSbots reversed the DSS-induced increase in intestinal permeability, and the permeability in the Cap-M@mSbots + MF group was further reduced, showing a significant difference compared to the Cap-M@mSbots-only group (
Figure 4F). Furthermore, we validated this conclusion using the colon epithelial cell line NCM460: under TNF-α-induced inflammatory injury, the transepithelial electrical resistance (TEER) ratio increased significantly compared to the normal group, while treatment with Cap-M@mSbots reversed the TNF-α-induced increase in TEER. The addition of magnetic control resulted in a barrier-protective effect significantly stronger than that of the mesoporous silica-encapsulated capsaicin treatment group alone (
Figure 4G).
Further, histopathological and molecular experiments provided direct evidence. Representative H&E staining images showed severe disruption of the colonic mucosal structure in the DSS model group, accompanied by epithelial loss and extensive inflammatory cell infiltration, while Cap-M@mSbots pretreatment alleviated the pathological damage. The mucosal structure in the Cap-M@mSbots + MF group was the most intact compared to the Cap-M@mSbots group, with regular crypt morphology and minimal inflammatory infiltration (
Figure 5A). At the molecular level, DSS induction significantly activated the NF-κB signaling pathway in colon tissues, manifested by upregulated expression of phosphorylated IκBα and p65 proteins. Cap-M@mSbots treatment suppressed the activation of this pathway, with the Cap-M@mSbots + MF group showing the strongest inhibitory effect, as the expression levels of key proteins were maximally suppressed (
Figure 5B,C). In summary, the data from this study, encompassing both in vivo and in vitro experiments, comprehensively demonstrate at macroscopic, molecular, and pathological levels that the mesoporous silica-loaded capsaicin nano-system (Cap-M@mSbots) exerts a clear preventive and protective effect against DSS-induced colitis. Moreover, with the addition of active magnetic field guidance, the therapeutic efficacy of this nano-system is significantly enhanced, as reflected in better weight maintenance, reduced inflammation levels, improved intestinal barrier integrity, and more pronounced histopathological improvement.
4. Discussion
In this study, addressing the critical pharmacological limitations of natural dietary active ingredients—specifically the poor oral bioavailability and mucosal irritation of capsaicin—we successfully engineered a magnetically actuated bio-hybrid nanorobot system, Cap-M@mSbots, for the active interventional prevention of colitis. The experimental results systematically validate the superior performance of this system from physicochemical properties to biological efficacy. Under the actuation of a rotating gradient magnetic field (80 mT), the Cap-M@mSbots overcame the limitation of individual Brownian motion to form reconfigurable, large-scale linear swarms. These swarms exhibited robust collective locomotion with a maximum velocity of 180.7 μm/s and demonstrated the capability to surmount millimeter-scale obstacles, ensuring precise navigation in the complex gastrointestinal environment. Biologically, in the DSS-induced colitis mouse model, the magnetically guided Cap-M@mSbots significantly mitigated pathological damage. Compared to the model group and passive administration, the active targeting strategy minimized weight loss, reduced the Disease Activity Index (DAI), and preserved colon length more effectively. Molecular mechanism analysis further confirmed that the system effectively inhibited the NF-κB signaling pathway, significantly downregulating the expression of pro-inflammatory cytokines (TNF-α) and phosphorylation levels of p65 and IκBα, while reversing the defects in intestinal permeability.
To highlight the innovation of this work, it is essential to compare it with existing therapeutic strategies. Unlike conventional mesoporous silica nanoparticles that rely on passive diffusion or the EPR effect, which are often limited by gastrointestinal peristalsis and mucus turnover, our Cap-M@mSbots utilize active magnetic propulsion to physically reside at the lesion site [
37]. Moreover, in contrast to chemically fueled micromotors that typically depend on short-lived, consumable fuels, our magnetic actuation offers a fuel-free and continuously controllable propulsion mechanism suitable for long-term physiological applications. Furthermore, distinct from systemic immunosuppressants that carry risks of broad side effects, or free oral capsaicin that causes direct gastric irritation, the core-shell structure of Cap-M@mSbots acts as a protective shield [
38,
39,
40]. This design avoids premature release in the stomach and ensures localized high-concentration release in the colon. Regarding the biocompatibility and metabolic fate of the nanorobots, a critical consideration is the particle dimension. Compared with magnetic nanomaterials reported in the literature for in vivo applications, Cap-M@mSbots possess a relatively large size. However, because Cap-M@mSbots move within the digestive system, do not actively enter the internal environment, and can be readily metabolized and excreted from the body, their larger size does not present a disadvantage in the context of prophylactic intervention for colitis [
41,
42,
43].
In summary, we developed a novel “active prevention” paradigm for IBD management. By transforming capsaicin from a dietary irritant into a targeted therapeutic agent via swarm-intelligent nanorobots, this study provides a highly efficient strategy for colitis intervention. The integration of the mesoporous silica shell—which enables high loading capacity and sustained release—with magnetic actuation ensures precise accumulation and prolonged retention at colonic lesion sites. This study not only demonstrates the therapeutic potential of Cap-M@mSbots in repairing the mucosal barrier and inhibiting inflammatory pathways but also offers a generic platform for the precise oral delivery of other hydrophobic bioactive compounds, paving the way for future clinical translation in the treatment of gastrointestinal diseases.